A 6-month Phase 3, Multicenter, Prospective, Randomized, Double-Blind, Vehicle-Controlled Study, to Evaluate the Efficacy and Safety of Topically Applied Clascoterone Solution for the Treatment of Androgenetic Alopecia in Males, Followed by a 6-month Single-Blind Treatment With Clascoterone or Vehicle Solution
Latest Information Update: 15 Feb 2024
At a glance
- Drugs Clascoterone (Primary)
- Indications Alopecia
- Focus Therapeutic Use
- Acronyms SCALP1
- Sponsors Cassiopea
- 09 Feb 2024 Status changed from not yet recruiting to recruiting.
- 15 Jun 2023 Status changed from planning to not yet recruiting.
- 03 Aug 2020 New trial record